Assembly Biosciences is advancing a new class of oral therapeutics for the treatment of hepatitis B (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Jun 3, 2020 at 1:30 PM EDT
May 7, 2020 at 1:30 PM PDT
May 4, 2020 at 9:30 AM CDT